MS Pharma ink deal for acquisition of Genepharm

05:46 EDT 17 Apr 2019 | Pharmafile

Jordanian firm MS Pharma has entered into an agreement to acquire 100% of the outstanding shares of Greek company Genepharm. The deal is expected to close by the end of April.

Genepharm, a company which develops, manufactures and out-licenses high value, generics, has a strong portfolio alongside an extensive network of 223 customers across 70 countires around the world.

The acquisition expands MS Pharma’s geographic footprint, which at the moment is mainly focused in the Turkey, the Middle East and Africa.

read more

Original Article: MS Pharma ink deal for acquisition of Genepharm


More From BioPortfolio on "MS Pharma ink deal for acquisition of Genepharm"

Quick Search


Relevant Topics

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...